logo
ProjectEnded

Regulating RAS Activity to Target RAS-Driven Cancers

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

More than a quarter of all cancers are driven by mutations in the RAS family of genes. Considering the key role of these oncogenes, and despite intensive effort, no effective anti-RAS strategies have successfully made it to the clinic. In our ERC-CoG project, we found that a class of scaffold proteins, expressed in cancer, bind to active/mutated forms of RAS proteins to moderate RAS signalling. Ac

Status
Closed
Sector
Hospital, Commercial
Location
Finland
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Regulating RAS Activity to Target RAS-Driven Cancers

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Regulating RAS Activity to Target RAS-Driven Cancers” is an infrastructure initiative in the Hospital sector, located in Finland. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

More than a quarter of all cancers are driven by mutations in the RAS family of genes. Considering the key role of these oncogenes, and despite intensive effort, no effective anti-RAS strategies have successfully made it to the clinic. In our ERC-CoG project, we found that a class of scaffold proteins, expressed in cancer, bind to active/mutated forms of RAS proteins to moderate RAS signalling. Accordingly, we find that loss of one of the scaffolding protein isoforms in RAS-mutant cancers triggers cytotoxic signalling, leading to cell death. As such, drugging this scaffold protein could not only i) represent a completely innovative approach to target RAS-driven cancers that exploits the oncogene’s function, but also ii) deliver the first truly effective cancer treatment for patients that do not respond to current standards of care. In this ERC-PoC, we aim to prove that therapeutic targeting of the scaffold protein is effective in vivo, and to explore the commercial avenues to exploit this finding.

Location

Country

Finland

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital, Commercial

Article published date

2026-02-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project